EP0822984A4 - Human tumor necrosis factor receptors - Google Patents

Human tumor necrosis factor receptors

Info

Publication number
EP0822984A4
EP0822984A4 EP95917662A EP95917662A EP0822984A4 EP 0822984 A4 EP0822984 A4 EP 0822984A4 EP 95917662 A EP95917662 A EP 95917662A EP 95917662 A EP95917662 A EP 95917662A EP 0822984 A4 EP0822984 A4 EP 0822984A4
Authority
EP
European Patent Office
Prior art keywords
necrosis factor
tumor necrosis
human tumor
factor receptors
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95917662A
Other languages
German (de)
French (fr)
Other versions
EP0822984A1 (en
Inventor
Jian Ni
Reiner Gentz
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP08013946A priority Critical patent/EP2017337A1/en
Publication of EP0822984A1 publication Critical patent/EP0822984A1/en
Publication of EP0822984A4 publication Critical patent/EP0822984A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95917662A 1995-04-27 1995-04-27 Human tumor necrosis factor receptors Ceased EP0822984A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08013946A EP2017337A1 (en) 1995-04-27 1995-04-27 Human tumor necrosis factor receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/005058 WO1996034095A1 (en) 1995-04-27 1995-04-27 Human tumor necrosis factor receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08013946A Division EP2017337A1 (en) 1995-04-27 1995-04-27 Human tumor necrosis factor receptors

Publications (2)

Publication Number Publication Date
EP0822984A1 EP0822984A1 (en) 1998-02-11
EP0822984A4 true EP0822984A4 (en) 2000-05-03

Family

ID=22249014

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08013946A Withdrawn EP2017337A1 (en) 1995-04-27 1995-04-27 Human tumor necrosis factor receptors
EP95917662A Ceased EP0822984A4 (en) 1995-04-27 1995-04-27 Human tumor necrosis factor receptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08013946A Withdrawn EP2017337A1 (en) 1995-04-27 1995-04-27 Human tumor necrosis factor receptors

Country Status (4)

Country Link
EP (2) EP2017337A1 (en)
JP (1) JPH11507205A (en)
AU (1) AU2363695A (en)
WO (1) WO1996034095A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5712381A (en) 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
JP4138013B2 (en) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ligand for receptor activator of NF-KAPPA B, a member of TNF superfamily
EP1007659B1 (en) 1997-01-14 2007-06-27 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6 alpha & 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US6013476A (en) 1997-04-02 2000-01-11 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor TR7
EP0869179A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Tumor necrosis related receptor, TR7
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
WO1998051346A1 (en) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Human tumor necrosis factor receptor-like 2 (tr2) antibodies
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
DE69939822D1 (en) 1998-05-14 2008-12-11 Immunex Corp METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTICS
US6287808B1 (en) 1998-09-03 2001-09-11 Millennium Pharmaceuticals, Inc. Molecules of the herpesvirus-entry-mediator-related protein family and uses thereof
JP2002529051A (en) * 1998-09-03 2002-09-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Novel molecules of the herpesvirus entry mediator-related protein family and uses thereof
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc Human tumor necrosis factor delta and epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
JP4309758B2 (en) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Antibodies that immunospecifically bind to TRAIL receptors
US20030068619A1 (en) * 2001-07-27 2003-04-10 Lal Preeti G. TNF receptor 2 related protein variant
WO2003011321A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of cobesin for the treatment of metabolic disorders
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin fusion proteins
EP1786463A4 (en) 2004-03-26 2009-05-20 Human Genome Sciences Inc Antibodies against nogo receptor
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2010045002A2 (en) 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
BR112012013330A2 (en) 2009-12-02 2017-03-28 Acceleron Pharma Inc compositions and methods for increasing fc fusion protein serum half life
BR112013010136A2 (en) 2010-10-25 2019-09-24 Univ Minnesota vaccine, therapeutic composition and methods for the treatment or inhibition of gliblastoma
EP2640744A4 (en) 2010-11-19 2014-05-28 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions and methods for increasing serum half-life
WO2014066700A1 (en) 2012-10-25 2014-05-01 Tocagen Inc. Retroviral vector with mini-promoter cassette

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438A2 (en) * 1989-04-21 1990-10-24 Synergen, Inc. TNF-receptor, TNF-binding protein and DNA coding therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438A2 (en) * 1989-04-21 1990-10-24 Synergen, Inc. TNF-receptor, TNF-binding protein and DNA coding therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C A SMITH ET AL: "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 248, no. 248, 25 May 1990 (1990-05-25), pages 1019 - 1022-1023, XP002107350, ISSN: 0036-8075 *
KWON B S ET AL: "A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 MAY 30) 272 (22) 14272-6., XP002131224 *
See also references of WO9634095A1 *

Also Published As

Publication number Publication date
EP2017337A1 (en) 2009-01-21
EP0822984A1 (en) 1998-02-11
AU2363695A (en) 1996-11-18
JPH11507205A (en) 1999-06-29
WO1996034095A1 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
EP0822984A4 (en) Human tumor necrosis factor receptors
EP0988371A4 (en) Human tumor necrosis factor receptor tr9
EP0871705A4 (en) Human ccn-like growth factor
ZA952587B (en) Human tumor necrosis factor receptor
PL328822A1 (en) Human bikinine
AU9013998A (en) Tumor necrosis factor receptor ztnfr-5
ZA953006B (en) Human bone stimulating factor
AU7705198A (en) Human tumor necrosis factor receptor tr10
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
EP0961782A4 (en) Human tumor necrosis factor receptor-like 2
GB9509572D0 (en) Cancer therapy
HUP9802589A3 (en) Bone stimulating factor
EP0961832A4 (en) Human tumor necrosis factor receptor-like genes
AU1541699A (en) Human tumor necrosis factor-r2-like proteins
EP1009431A4 (en) Human tumor necrosis factor receptor-like 2 (tr2) antibodies
EP0574257A3 (en) Amino-hydroxy-methyl-isoxazole-propionate binding human glutamate receptors.
AU5471098A (en) Bone stimulating factor
AU9130598A (en) Tumor necrosis factor receptor ztnfr-6
EP0792282A4 (en) Human endothelin-bombesin receptor
ZA968062B (en) Bone stimulating factor
GB9508640D0 (en) Sunbeds
ZA954143B (en) Human tumor necrosis factor receptors.
EP0797592A4 (en) Human stanniocalcin-alpha
AU2159995A (en) Human tumor necrosis factor receptor
EP0795006A4 (en) HUMAN MutT2

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000316

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030425

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080827